ELTX
Elicio Therapeutics, Inc.Healthcare·Biotechnology
$11.44
$218M market cap
Revenue
$0.0M
Free Cash Flow
$-18.5M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targete
2-Year Price History
$9.95+27.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -10.3 | -10.6 | -11.8 | -11.6 | -11.6 | -0.0 | 15.0 | 4.9 | 18.2 | -871.7% | -25.3x | -- |
| Act | 2025-Q4 | 0.0 | -7.1 | -8.8 | -7.7 | -6.8 | -6.8 | -0.0 | 18.6 | 5.1 | 15.3 | -627.5% | -21.1x | -- |
Valuation & Metrics
Market Stats
Price$11.44
Market Cap$218M
Enterprise Value$208M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-8.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-19.5M
Free Cash Flow$-18.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-749.6%
WC Change % Rev0.0%
Interest Coverage-23.4x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.7M
Days to Cover11.6
Change (vs Prior)+14.9%
Need at least 2 settlement dates for chart
Employees
Headcount32
Revenue / Employee$0
Gross Profit / Employee$-9,031
Cash Runway
9.7months
CRITICAL
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
9.6%(+6.2% YoY)
37 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
5.1%(+3.4% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.3% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC | $6.7M | $6.16 | +$0 | +$0 | -5.6% | $180M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $5.5M | $10.69 | +$5.5M | +$5.5M | — | $4.04T |
| BALYASNY ASSET MANAGEMENT LLC | $2.6M | $10.84 | +$1.1M | +$2.6M | -0.4% | $48.01B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.4M | $7.26 | +$28K | +$617K | +2.3% | $1.61T |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | $10.49 | +$1000K | +$1.3M | +1.2% | $63.91B |
| MILLENNIUM MANAGEMENT LLC | $992K | $9.27 | +$747K | +$433K | -0.5% | $127.40B |
| MARSHALL WACE, LLP | $797K | $10.16 | −$456K | +$797K | +0.6% | $92.71B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $757K | $9.87 | +$72K | +$422K | -0.6% | $77.14B |
| VANGUARD FIDUCIARY TRUST COPassive | $740K | $10.69 | +$740K | +$740K | — | $395.83B |
| NORTHERN TRUST CORPPassive | $639K | $6.14 | +$74K | +$84K | -0.2% | $755.34B |
| GOLDMAN SACHS GROUP INC | $618K | $10.69 | +$618K | +$618K | -0.2% | $760.93B |
| 683 Capital Management, LLC | $603K | $7.96 | +$0 | +$603K | -2.2% | $1.02B |
| STATE STREET CORPPassive | $541K | $8.72 | +$46K | +$310K | -0.2% | $2.89T |
| BlackRock, Inc.Passive | $541K | $6.43 | +$58K | +$121K | -0.2% | $5.69T |
| UBS Group AG | $361K | $7.30 | +$19K | +$134K | -0.3% | $562.11B |
| MORGAN STANLEY | $346K | $9.51 | +$191K | +$337K | -0.3% | $1.65T |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $321K | $10.69 | +$321K | +$321K | -0.6% | $247M |
| CM Management, LLC | $267K | $7.35 | +$0 | −$321K | -4.5% | $120M |
| HRT FINANCIAL LP | $231K | $10.69 | +$231K | +$231K | -0.6% | $39.46B |
| Hudson Bay Capital Management LP | $216K | $5.61 | −$1.7M | −$1.7M | +1.9% | $15.12B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-2.22%
avg per quarter
Holders (ex-self)
-2.27%
excl. this stock
Buyers (this Q)
-0.19%
29 buyers · $0.01B in
Sellers (this Q)
+1.40%
8 sellers · $0.00B out
alpha coverage: 78% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+21.6%
how holders react when this stock falls
On quiet Qs
+28.7%
−10% to +10% baseline
On rallies (+10%+)
-10.9%
how they react when this stock rises
Holders' portfolio flow this Q
+0.8%
inflows — adds are organic
Sellers' portfolio flow this Q
-1.0%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.2%
Holder mid (any stock)
-5.0%
Holder rally (any stock)
-7.7%
Biggest decreases this quarter
Hudson Bay Capital Management LP−$1.7Mα+1.9MARSHALL WACE, LLP−$456Kα+0.6CIBC Bancorp USA Inc.exited−$195KSquarepoint Ops LLCexited−$133KOCCUDO QUANTITATIVE STRATEGIES LPexited−$126KJefferies Financial Group Inc.exited−$95KPoint72 Asset Management, L.P.exited−$93KQuadrature Capital Ltd−$3Kα+1.3GROUP ONE TRADING LLCexited−$3KROYAL BANK OF CANADAexited−$2K
New buyers this quarter
Top-5 holders · 62.5%
Knoll Capital Management, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
BALYASNY ASSET MANAGEMENT LLC--
GEODE CAPITAL MANAGEMENT, LLC--
RENAISSANCE TECHNOLOGIES LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Knoll Capital Management, LLC631KBALYASNY ASSET MANAGEMENT LLC245KRENAISSANCE TECHNOLOGIES LLC122KHudson Bay Capital Management LP20KMILLENNIUM MANAGEMENT LLC93KMARSHALL WACE, LLP75KNantahala Capital Management, LLC—GOLDMAN SACHS GROUP INC58KCM Management, LLC25K683 Capital Management, LLC56K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$17.004860.0%
Last Year (2 analysts)$17.004860.0%
Current Price$11.44
Analyst Ratings
1
1
Buy: 1Hold: 1Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
19.3%retail-4.1pp
14.6%dark+0.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Elicio Therapeutics: A Related-Party Liquidity Treadmill Facing Severe Dilution
Overall Risk
9/10
Fraud
3/10
Dilution
9/10
Insolvency
9/10
Earnings Overstated
4/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
9/10
Hidden Upside
3/10
Contextually Acceptable
4/10